Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

Name: Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial
Creator: Bardur Sigurgeirsson
Published: 2021-05-28T20:26:33.273Z
Keywords: Psoriasis

Sigurgeirsson, Bardur; Browning, John; Tyring, Stephen; Szepietowski, Jacek; Rivera‐Díaz, Raquel; Effendy, Isaak; Keefe, Deborah; Bruin, Gerard; Paguet, Bertrand; Fu, Rong; Hampele, Isabelle; Reinhardt, Maximilian; Patekar, Manmath

doi:10.17632/5pk8xf8h68.1

Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

Published: 28 May 2021| Version 1 | DOI: 10.17632/5pk8xf8h68.1

Contributors:

Bardur Sigurgeirsson, John Browning, Stephen Tyring, Jacek Szepietowski, Raquel Rivera‐Díaz, Isaak Effendy, Deborah Keefe, Gerard Bruin, Bertrand Paguet, Rong Fu, Isabelle Hampele, Maximilian Reinhardt, Manmath Patekar

Description

Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

Description

Files

Categories

Licence